Metabolic Brain Disease

, Volume 19, Issue 3–4, pp 421–429

Fatigue Complicating Chronic Liver Disease

  • E. Anthony Jones

DOI: 10.1023/B:MEBR.0000043986.70972.3b

Cite this article as:
Jones, E.A. Metab Brain Dis (2004) 19: 421. doi:10.1023/B:MEBR.0000043986.70972.3b


Fatigue is common and can be profound in patients with chronic liver diseases, such as primary biliary cirrhosis (PBC) and chronic hepatitis C. The pathogenesis of fatigue in such patients is unknown; it may be related to infection with the hepatitis C virus or the pathophysiology of cholestasis in PBC, to a psychological reaction to knowledge of the diagnosis, or to the presence of chronic liver disease. A major problem in evaluating a treatment for fatigue in a randomized controlled trial is the inherent subjectivity of fatigue and the lack of a satisfactory objective quantitative primary efficacy endpoint. Experimental studies in rats and male athletes have implicated the serotonin neurotransmitter system in fatigue of central origin. Administration of the 5-HT3 serotonin receptor subtype antagonist, ondansetron, has been associated with substantial sustained clinical ameliorations of profound fatigue in at least some patients with chronic liver disease.

Primary biliary cirrhosis chronic hepatitis C fatigue serotonin ondansetron 

Copyright information

© Plenum Publishing Corporation 2004

Authors and Affiliations

  • E. Anthony Jones
    • 1
  1. 1.Department of Gastrointestinal and Liver DiseasesAcademic Medical CenterThe Netherlands

Personalised recommendations